Bevacizumab
Top View
- Zydus Launches Ujvira (Trastuzumab Emtansine), a Breakthrough in Breast Cancer Treatment
- NCCN Guidelines for Patients Metastatic Breast Cancer
- MAHA) in Patients Treated with Avastin® (Bevacizumab) and Sunitinib Malate
- 125427Orig1s000
- Avastin, INN-Bevacizumab
- Antitumor Activity of Capecitabine and Bevacizumab Combination in a Human Estrogen Receptor-Negative Breast Adenocarcinoma Xenograft Model
- (INN) for Biological and Biotechnological Substances
- Phase II Trial of FOLFOX6, Bevacizumab, and Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- Gastric Cancers
- Correlation Between the Qualification for Bevacizumab Use and The
- Bevacizumab, Sunitinib: Osteonecrosis of the Jaw Venous Sclerosants
- Real-World Effectiveness of Post-Trastuzumab Emtansine
- Evolution of Escherichia Coli Expression System in Producing Antibody Recombinant Fragments
- Vectibix (Panitumumab) Is a Recombinant, Human Igg2 Kappa Monoclonal Antibody That Binds Specifically to the Human Epidermal Growth Factor Receptor (EGFR)
- SUTENT (Sunitinib Malate)
- DRUG NAME: Bevacizumab
- Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: a Decision Analysis
- An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies